Unless you are a short term investor in MNKD, you should look at the large short interest as very bullish. If you have faith in MNKD and have done your due diligence, sooner or later there is going to be that unexpected or expected piece of news that is going to send the shares flying. Then the squeeze begins. So please come in said the spider to the fly.
The Spider and the Fly
by Mary Howitt (1799-1888)
“Will you step into my parlor?” said the spider to the fly;
“’Tis the prettiest little parlor that ever you did spy.
The way into my parlor is up a winding stair,
And I have many pretty things to show when you are there.”
“O no, no,” said the little fly, “to ask me is in vain,
For who goes up your winding stair can ne’er come down again.”
“I’m sure you must be weary, dear, with soaring up so high;
Will you rest upon my little bed?” said the spider to the fly.
“There are pretty curtains drawn around, the sheets are fine and thin,
And if you like to rest awhile, I’ll snugly tuck you in.”
“O no, no,” said the little fly, “for I’ve often heard it said,
They never, never wake again, who sleep upon your bed.”
Said the cunning spider to the fly, “Dear friend, what shall I do,
To prove the warm affection I’ve always felt for you?
I have within my pantry good store of all that’s nice;
I’m sure you’re very welcome; will you please to take a slice?”
“O no, no,” said the little fly, “kind sir, that cannot be;
I’ve heard what’s in your pantry, and I do not wish to see.”
“Sweet creature!” said the spider, “You’re witty and you’re wise!
How handsome are your gauzy wings, how brilliant are your eyes!
I have a little looking-glass upon my parlor shelf,
If you’ll step in one moment, dear, you shall behold yourself.”
“I thank you, gentle sir,” she said, “for what you’re pleased to say,
And bidding you good-morning now, I’ll call another day.”
For the rest google The Spider and the Fly by Mary Howitt
Renewal rate looks good too, up 25% week to week.
BUZZ-Pricey borrowing costs don't stop MannKind short sellers
4:09 PM ET, 06/10/2015 - Reuters
** Shares of drugmaker MannKind slump 10.6 pct on Wednesday, cutting gain in 2015 to 14 pct ** Annualized cost of borrowing MannKind stock for shorting is at over 90 percent, according to SunGard's Astec Analytics ** Cost of borrowing MannKind stock was 85 percent two weeks ago, according to Sungard ** Stock a favorite of short sellers due partly to worries about weak sales of MannKind's much-hyped Afrezza inhalable insulin product ** Short interest at end of May grew to 32 pct of outstanding shares from 25 pct at end of April ** Company scores 94 out of 100 for likelihood of short squeeze, according to Thomson Reuters StarMine model. That's up from 92 last week
What 2 dozen countries? Are you saying they accept prescriptions now or awaiting AFREZZA approval? What is source of your information? Good info. if verified.
A 19 spage booklet entitled "Discover another approach to insulin"
see twitter /search?q=%23afrezza&src=typd
I am reasonably confident that MNKD breaks even with scripts counts of between 50,000 and 70,000 a year. Might be significantly less dependent on cost of the product. That comes to script counts of between 960 and 1350 a week. I tend to think in reality script counts in the 900 range will be more than sufficient. I expect to see that by the end of the year and probably on a trend line that shows them going significantly higher. If script counts keep growing, MNKD is cheaply priced today.
Assuming AFREZZA works as well as early adopters are saying, we need to figure out how this translates to share earnings. Based on a 450 million share count (I know that is 50 million above issued shares but being conservative) and given the price of a script reported by Symphony of $470+, what will it take in scripts written given the Sanofi partnership for MNKD to make $1.00 a share, i.e, to gross $450 million in revenue - realize that doesn't include cost of production, but its a start.
Here is a down and dirty back of the envelope calculation. AFREZZA according to Symphony data has an average selling price of $470 a script. Assuming a 100% markup (and it is probably much higher but lets be conservative), that gives a cost to Mannkind/Sanofi of $235 a script and a profit of $235 a script. (note this is very conservative as the markup is probably way higher). MNKD under the partnership agreement gets 35% of it or $82.25 a script. This assumes the $235 is all profit, wildly optimistic I know, but this is a back of the envelope calculation. So to gross $450,000,000 AFREZZA needs 5,471,124 scripts. According to Symphony data as of the week ending April 17, 2015, there were cumulative scripts of 1945. We're 00036% of the way there. Note: MNKD's profit per script may be consideraly higher so that would very significantly change the calculation.
But more optimistically . . .to make a penny a share the number of scripts is only 54,712 and we're 3.6% of the way there. So MANNKIND is almost 4% of the way to breaking even!!!! And that with virtually no publicity but social media.
Don't forget under agreement with Sanofi, Sanofi has a right of first refusal, i.e, to match any offer.